Table 1 Baseline characteristics
Variables | level | Overall | >=55 | < 55 | p |
|---|---|---|---|---|---|
n | 103 | 35 | 68 | ||
Recipients | |||||
Sex, n (%) | F | 12 (11.7) | 5 ( 14.3) | 7 ( 10.3) | 0.55 |
M | 91 (88.3) | 30 ( 85.7) | 61 ( 89.7) | ||
Age, years (mean (SD)) | 50.26 (9.16) | 59.95 (4.10) | 45.27 (6.71) | < 0.001 | |
BMI, kg/cm2 (mean (SD)) | 24.68 (3.05) | 24.73 (2.52) | 24.65 (3.31) | 0.906 | |
Dialysis, n (%) | No | 13 (12.6) | 5 ( 14.3) | 8 ( 11.8) | 0.715 |
Yes | 90 (87.4) | 30 ( 85.7) | 60 ( 88.2) | ||
DM duration,, years (mean (SD)) | 19.12 (10.46) | 20.04 (8.94) | 18.64 (11.19) | 0.522 | |
CVD_before_transplantation, n (%) | Yes | 30 (29.1) | 14 ( 40.0) | 16 ( 23.5) | 0.081 |
No | 73 (70.9) | 21 ( 60.0) | 52 ( 76.5) | ||
CRD_before_transplantation, n (%) | Yes | 14 (13.6) | 4 ( 11.4) | 10 ( 14.7) | 0.646 |
No | 89 (86.4) | 31 ( 88.6) | 58 ( 85.3) | ||
PRA, n (%) | No | 92 (89.3) | 32 ( 91.4) | 60 ( 88.2) | 0.619 |
Yes | 11 (10.7) | 3 ( 8.6) | 8 ( 11.8) | ||
Induction, n (%) | Anti-IL-2R | 5 ( 4.9) | 2 ( 5.7) | 3 ( 4.4) | 0.771 |
rATG | 98 (95.1) | 33 ( 94.3) | 65 ( 95.6) | ||
CNI, n (%) | Tac | 77 (82.8) | 26 ( 83.9) | 51 ( 82.3) | 0.846 |
CsA | 16 (17.2) | 5 ( 16.1) | 11 ( 17.7) | ||
Antiproliferative_drugs, n (%) | EC-MPS | 47 (52.8) | 15 ( 50.0) | 32 ( 54.2) | 0.208 |
Mizoribine | 6 ( 6.7) | 4 ( 13.3) | 2 ( 3.4) | ||
MMF | 36 (40.4) | 11 ( 36.7) | 25 ( 42.4) | ||
C-peptide, ng/mL | 2.35 (0.97) | 2.36 (1.00) | 2.34 (0.97) | 0.957 | |
Followuptime, years (mean (SD)) | 4.05 (1.43) | 3.96 (1.61) | 4.10 (1.34) | 0.65 | |
Donors | |||||
Donor_age, years (mean (SD)) | 30.18 (13.62) | 31.15 (11.64) | 29.61 (14.74) | 0.608 | |
Donor_Sex, n (%) | F | 17 (16.5) | 3 ( 8.6) | 14 ( 20.6) | 0.12 |
M | 86 (83.5) | 32 ( 91.4) | 54 ( 79.4) | ||
Donor_BMI, kg/cm2 (mean (SD)) | 27.87 (12.87) | 31.87 (9.25) | 25.94 (14.02) | 0.145 | |
KidCIT, minute (mean (SD)) | 4.12 (1.18) | 4.50 (1.24) | 3.97 (1.13) | 0.091 |